Meeting
2015 Gastrointestinal Cancers Symposium
Triplet chemotherapy (TC) with FOLFIRINOX regimen in metastatic colorectal cancer (mCRC): Experience of two French centres.
Authors
Emmanuelle Samalin
Institut régional du Cancer de Montpellier, Val d'Aurelle, Montpellier, France
Emmanuelle Samalin , Christelle De La Fouchardiere , Simon Thézenas , Matthieu Sarabi , Eric Assenat , Fabienne Portales , Sebastien Carrere , Michel Rivoire , Philippe Rouanet , Jean-Pierre Bleuse , François Quenet , Marc Ychou
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 776)
DOI
10.1200/jco.2015.33.3_suppl.776
Abstract #
776
Poster Bd #
F14
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Triplet chemotherapy (TC) with FOLFIRINOX regimen in metastatic colorectal cancer (mCRC): Experience of the Val d'Aurelle Center.
First Author: Emmanuelle Samalin
Poster
2016 Gastrointestinal Cancers Symposium
Treatment patterns and outcomes in patients with KRAS wild type (WT) metastatic colorectal cancer (mCRC) treated in first line with bevacizumab (B) or cetuximab (C) containing regimens.
First Author: Arthur C. Houts
Poster
2015 ASCO Annual Meeting
A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405.
First Author: Federico Innocenti
Poster
2015 Gastrointestinal Cancers Symposium
E7208: A randomized phase II trial of irinotecan and cetuximab (IC) versus IC plus ramucirumab (ICR) in second line therapy of KRAS wild type colorectal cancer (CRC).
First Author: Howard S. Hochster